On August 10, 2023 XNK Therapeutics AB ("XNK") reported that the company has entered into an agreement with a US biotechnology company (Press release, XNK Therapeutics, AUG 10, 2023, View Source [SID1234634241]). Under the agreement the parties will perform preclinical evaluation of XNK’s autologous NK cell therapy candidate XNK02 in combination with a drug candidate currently in clinical development by the US company. The combination will initially be tested against acute myeloid leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration supplements XNK’s current collaborations in the field of AML with the University of Texas MD Anderson Cancer Center.